Xinping Chi, Qi Bi, Li You, Yalin Zhou, Chunshan Zhao
{"title":"NLR对高血压发生和临床结局的预测价值：一项系统回顾和荟萃分析。","authors":"Xinping Chi, Qi Bi, Li You, Yalin Zhou, Chunshan Zhao","doi":"10.1080/17520363.2025.2542111","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This paper aims to perform a meta-analysis to provide the most updated and comprehensive evidence on the link between neutrophil-lymphocyte ratio (NLR) and the development and prognosis of hypertension.</p><p><strong>Materials & methods: </strong>Cochrane Library, PubMed, Embase, and Web of Science were thoroughly searched for studies published from the inception of the databases up to 4 May 2024 using the keywords \"Lymphocytes,\" \"Neutrophils,\" \"Ratio,\" and \"Hypertension.\" The odds ratios (OR) and 95% confidence intervals (CI) were extracted for random-effects meta-analysis. We employed Egger's test to check publication bias, sensitivity analyses to identify studies that significantly impacted the meta-analysis results, and subgroup analyses to ascertain the source of heterogeneity.</p><p><strong>Results: </strong>10 articles involving 78,194 patients were enrolled. The pooled data indicated that NLR was a significant predictor of hypertension risk (OR = 1.11, 95% CI = 1.05-1.17, <i>p</i> = 0.004). Additionally, NLR was notably linked with all-cause (OR = 2.02, 95% CI = 1.29-3.15, <i>p</i> = 0.002) and cardiovascular deaths (OR = 2.10, 95% CI = 1.51-2.61, <i>p</i> < 0.0001) in hypertensive patients. Sensitivity analyses validated the robustness of the findings, and subgroup analyses ascertained a source of heterogeneity.</p><p><strong>Conclusion: </strong>NLR is a reliable and valuable biomarker for predicting both the risk of hypertension and outcomes in hypertensive patients.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"783-791"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416170/pdf/","citationCount":"0","resultStr":"{\"title\":\"Predictive value of NLR for the occurrence and clinical outcomes of hypertension: a systematic review and meta-analysis.\",\"authors\":\"Xinping Chi, Qi Bi, Li You, Yalin Zhou, Chunshan Zhao\",\"doi\":\"10.1080/17520363.2025.2542111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>This paper aims to perform a meta-analysis to provide the most updated and comprehensive evidence on the link between neutrophil-lymphocyte ratio (NLR) and the development and prognosis of hypertension.</p><p><strong>Materials & methods: </strong>Cochrane Library, PubMed, Embase, and Web of Science were thoroughly searched for studies published from the inception of the databases up to 4 May 2024 using the keywords \\\"Lymphocytes,\\\" \\\"Neutrophils,\\\" \\\"Ratio,\\\" and \\\"Hypertension.\\\" The odds ratios (OR) and 95% confidence intervals (CI) were extracted for random-effects meta-analysis. We employed Egger's test to check publication bias, sensitivity analyses to identify studies that significantly impacted the meta-analysis results, and subgroup analyses to ascertain the source of heterogeneity.</p><p><strong>Results: </strong>10 articles involving 78,194 patients were enrolled. The pooled data indicated that NLR was a significant predictor of hypertension risk (OR = 1.11, 95% CI = 1.05-1.17, <i>p</i> = 0.004). Additionally, NLR was notably linked with all-cause (OR = 2.02, 95% CI = 1.29-3.15, <i>p</i> = 0.002) and cardiovascular deaths (OR = 2.10, 95% CI = 1.51-2.61, <i>p</i> < 0.0001) in hypertensive patients. Sensitivity analyses validated the robustness of the findings, and subgroup analyses ascertained a source of heterogeneity.</p><p><strong>Conclusion: </strong>NLR is a reliable and valuable biomarker for predicting both the risk of hypertension and outcomes in hypertensive patients.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"783-791\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416170/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2542111\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2542111","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
目的：本文旨在通过荟萃分析，为中性粒细胞-淋巴细胞比率（NLR）与高血压的发展和预后之间的关系提供最新和全面的证据。材料与方法：通过关键词“淋巴细胞”、“中性粒细胞”、“比率”和“高血压”，对Cochrane图书馆、PubMed、Embase和Web of Science从数据库建立到2024年5月4日发表的研究进行了全面检索。提取优势比（OR）和95%置信区间（CI）进行随机效应荟萃分析。我们采用Egger检验检查发表偏倚，采用敏感性分析确定对meta分析结果有显著影响的研究，采用亚组分析确定异质性的来源。结果：纳入10篇文章，78,194例患者。合并数据显示NLR是高血压风险的重要预测因子（OR = 1.11, 95% CI = 1.05-1.17, p = 0.004）。此外，NLR与全因死亡（OR = 2.02, 95% CI = 1.29-3.15, p = 0.002）和心血管死亡（OR = 2.10, 95% CI = 1.51-2.61, p）显著相关。结论：NLR是预测高血压患者高血压风险和预后的可靠且有价值的生物标志物。
Predictive value of NLR for the occurrence and clinical outcomes of hypertension: a systematic review and meta-analysis.
Aim: This paper aims to perform a meta-analysis to provide the most updated and comprehensive evidence on the link between neutrophil-lymphocyte ratio (NLR) and the development and prognosis of hypertension.
Materials & methods: Cochrane Library, PubMed, Embase, and Web of Science were thoroughly searched for studies published from the inception of the databases up to 4 May 2024 using the keywords "Lymphocytes," "Neutrophils," "Ratio," and "Hypertension." The odds ratios (OR) and 95% confidence intervals (CI) were extracted for random-effects meta-analysis. We employed Egger's test to check publication bias, sensitivity analyses to identify studies that significantly impacted the meta-analysis results, and subgroup analyses to ascertain the source of heterogeneity.
Results: 10 articles involving 78,194 patients were enrolled. The pooled data indicated that NLR was a significant predictor of hypertension risk (OR = 1.11, 95% CI = 1.05-1.17, p = 0.004). Additionally, NLR was notably linked with all-cause (OR = 2.02, 95% CI = 1.29-3.15, p = 0.002) and cardiovascular deaths (OR = 2.10, 95% CI = 1.51-2.61, p < 0.0001) in hypertensive patients. Sensitivity analyses validated the robustness of the findings, and subgroup analyses ascertained a source of heterogeneity.
Conclusion: NLR is a reliable and valuable biomarker for predicting both the risk of hypertension and outcomes in hypertensive patients.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
